Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
REZZAYO (REZAFUNGIN ACETATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
REZZAYO
NDA
Get alerts
REZAFUNGIN ACETATE | N217417 | MUNDIPHARMA GMBH
1 strength
7 unique patents
3 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
Medicare B
Approvals
Label
Products
Patent Timeline
7 unique patents, 3 exclusivities by expiration date
Active (7)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
Today
8722619
May. 9, 2036
9526835
Mar. 14, 2033
10702573
Mar. 14, 2033
11197909
Jul. 14, 2038
11654196
Mar. 2, 2032
11712459
Mar. 15, 2037
11819533
Jul. 11, 2038
NCE
Mar. 22, 2028
ODE-426
Mar. 22, 2030
GAIN
Mar. 22, 2035
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 200MG BASE/VIAL
RLD
7 patents
3 exclusivities
▴
POWDER;INTRAVENOUS | Approved: Mar 22, 2023
Patents (7)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8722619
May 9, 2036
—
Yes
Yes
U-3566
TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
—
9526835
Mar 14, 2033
—
Yes
Yes
U-3566
TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
—
10702573
Mar 14, 2033
—
Yes
Yes
U-3566
TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
—
11197909
Jul 14, 2038
—
Yes
Yes
U-3566
TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
—
11654196
Mar 2, 2032
—
Yes
Yes
U-3566
TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
—
11712459
Mar 15, 2037
—
—
Yes
U-3566
TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
—
11819533
Jul 11, 2038
—
Yes
Yes
U-3566
TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
—
Exclusivities (3)
Code
Date
Status
GAIN
Mar 22, 2035
Active
NCE
Mar 22, 2028
Active
ODE-426
Mar 22, 2030
Active